Solara Active Pharma Sciences Publishes Newspaper Ads for Rights Issue Final Call
Solara Active Pharma Sciences has published newspaper advertisements in Business Standard and Pratahkal informing shareholders about the second and final call of ₹112.50 per share on partly paid-up equity shares. The company set April 2, 2026, as the record date and announced trading suspension from April 1, 2026, while also providing a re-lodgement window for previously rejected physical share transfers.

*this image is generated using AI for illustrative purposes only.
Solara Active Pharma Sciences Limited has successfully concluded its Rights Issue Committee meeting and published newspaper advertisements informing shareholders about the second and final call of ₹112.50 per share on partly paid-up equity shares. The pharmaceutical company has set April 2, 2026, as the record date for determining eligible shareholders who must pay the call money.
Committee Meeting Outcomes and Advertisement Publication
Following the Rights Issue Committee meeting held on March 24, 2026, the company published advertisements in Business Standard and Pratahkal newspapers on March 25, 2026. The advertisements inform shareholders about the second and final call and the record date for determining eligible shareholders. These advertisements are also available on the company's website at https://solara.co.in/investor-relations/newspaper-publications .
| Final Call Details: | Information |
|---|---|
| Call Amount: | ₹112.50 per share |
| Face Value Component: | ₹3.00 per share |
| Securities Premium: | ₹109.50 per share |
| Call Type: | Second and Final Call |
| Record Date: | April 2, 2026 |
| Advertisement Date: | March 25, 2026 |
| Publications: | Business Standard, Pratahkal |
Trading Suspension and Shareholder Obligations
The company has officially notified that trading in partly paid-up equity shares (ISIN: IN9624201022) will be suspended on stock exchanges with effect from April 1, 2026. Shareholders holding partly paid-up equity shares issued under the rights offering must pay the final call amount of ₹112.50 per share to convert these into fully paid-up equity shares. Call notices will be dispatched to eligible shareholders for payment of the call amount.
Share Transfer Re-lodgement Window
The company has also announced a re-lodgement window for physical share transfer requests that were previously rejected. Shareholders can re-lodge transfer requests from February 5, 2024, to February 4, 2027, for transfers that were rejected before April 1, 2019, or those lodged before April 1, 2019, but rejected due to document deficiencies. The re-lodged securities will be transferred only in demat mode once all documents are verified by the Registrar and Transfer Agent, Cameo Corporate Services Limited.
Regulatory Compliance and Documentation
Company Secretary and Compliance Officer Pooja Jaya Kumar has signed all official communications to stock exchanges, ensuring proper regulatory disclosure under SEBI Listing Regulations. The company maintains full compliance with Regulation 30 and 42 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, throughout the rights issue process. The comprehensive documentation includes the original Letter of Offer dated May 9, 2024, and all subsequent regulatory filings related to the rights issue completion.
Historical Stock Returns for Solara Active Pharma Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.70% | +4.26% | +3.01% | -21.35% | -7.09% | -63.21% |
How will Solara Active Pharma Sciences utilize the additional capital raised from this final call to expand its pharmaceutical operations or R&D capabilities?
What potential impact could non-payment by some shareholders have on Solara's capital structure and the forfeiture of partly paid-up shares?
Will the completion of this rights issue position Solara for potential acquisitions or strategic partnerships in the pharmaceutical sector?


































